Ftse Mib
36.025,89
-1,22%
DAX
21.328,30
-1,76%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
0,00%
Bitcoin
95.004,88
-2,76%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Trillium Therapeutics Inc (TRIL) Trillium Therapeutics Inc (TRIL) Notizie

TRIL

Trillium Therapeutics (TRIL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TRIL
DataOraFonteTitoloSimboloCompagnia
22/11/202112:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:TRILTrillium Therapeutics Inc
19/11/202121:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TRILTrillium Therapeutics Inc
19/11/202112:44Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:TRILTrillium Therapeutics Inc
17/11/202122:02Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:TRILTrillium Therapeutics Inc
17/11/202122:02Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:TRILTrillium Therapeutics Inc
17/11/202122:01Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:TRILTrillium Therapeutics Inc
17/11/202115:28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TRILTrillium Therapeutics Inc
17/11/202115:24Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:TRILTrillium Therapeutics Inc
15/11/202123:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TRILTrillium Therapeutics Inc
12/11/202113:01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TRILTrillium Therapeutics Inc
28/10/202123:00GlobeNewswire Inc.Trillium Therapeutics Receives Final Court Order Approving ArrangementNASDAQ:TRILTrillium Therapeutics Inc
26/10/202123:15GlobeNewswire Inc.Trillium Securityholders Approve Acquisition by PfizerNASDAQ:TRILTrillium Therapeutics Inc
20/10/202112:05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TRILTrillium Therapeutics Inc
27/09/202112:08Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:TRILTrillium Therapeutics Inc
13/09/202122:55Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:TRILTrillium Therapeutics Inc
24/08/202123:14TipRanksPfizer to Purchase Rest of Trillium; Analysts Have Their SayNASDAQ:TRILTrillium Therapeutics Inc
23/08/202112:45GlobeNewswire Inc.Pfizer to Acquire Trillium Therapeutics Inc.NASDAQ:TRILTrillium Therapeutics Inc
13/08/202113:00GlobeNewswire Inc.Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial ResultsNASDAQ:TRILTrillium Therapeutics Inc
09/08/202113:00GlobeNewswire Inc.Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid LeukemiaNASDAQ:TRILTrillium Therapeutics Inc
06/07/202113:00GlobeNewswire Inc.Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Ve...NASDAQ:TRILTrillium Therapeutics Inc
02/07/202122:35Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TRILTrillium Therapeutics Inc
30/06/202113:00GlobeNewswire Inc.Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of DirectorsNASDAQ:TRILTrillium Therapeutics Inc
29/06/202113:00GlobeNewswire Inc.Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Lei...NASDAQ:TRILTrillium Therapeutics Inc
26/06/202100:28GlobeNewswire Inc.Trillium Therapeutics Joins Russell 2000® and 3000® IndicesNASDAQ:TRILTrillium Therapeutics Inc
09/06/202113:00GlobeNewswire Inc.Trillium Announces Voting Results From the Annual General and Special Meeting of ShareholdersNASDAQ:TRILTrillium Therapeutics Inc
07/05/202113:00GlobeNewswire Inc.Trillium Therapeutics Reports First Quarter 2021 Operating and Financial ResultsNASDAQ:TRILTrillium Therapeutics Inc
28/04/202113:01GlobeNewswire Inc.Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dex...NASDAQ:TRILTrillium Therapeutics Inc
28/04/202113:00GlobeNewswire Inc.Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid...NASDAQ:TRILTrillium Therapeutics Inc
22/04/202113:00GlobeNewswire Inc.Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021NASDAQ:TRILTrillium Therapeutics Inc
18/03/202121:05GlobeNewswire Inc.Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D DayNASDAQ:TRILTrillium Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TRIL

La tua Cronologia

AMEX
RDIV
Invesco S&P Ultra Divide...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci